Is ADXSD or NOBL a better dividend investment in 2026?

ADXSD currently yields 51.95% with a 5% 5-year dividend growth rate. NOBL yields 4.00% with 5% growth. The better choice depends on your goal: ADXSD offers higher current income.

What is the dividend yield difference between ADXSD and NOBL?

ADXSD has a forward dividend yield of 51.95% ($2.00/share annually). NOBL yields 4.00% ($2.00/share annually). The yield gap is 47.95 percentage points.

Home › Compare › ADXSD vs NOBL

ADXSD vs NOBL: Dividend Comparison 2026

ADXSD yields 51.95% · NOBL yields 4.00%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 ADXSD wins by $407.4K in total portfolio value

INVESTMENT

TIME HORIZON10 years

ADXSD

● Live price

51.95%

Share price

$3.85

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$435.5K

Annual income

$90,970.08

Full ADXSD calculator →

NOBL

● Live price

4.00%

Share price

$50.00

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$28.0K

Annual income

$899.19

Full NOBL calculator →

Portfolio growth — ADXSD vs NOBL

📍 ADXSD pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	ADXSD	NOBL
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, ADXSD + NOBL cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

ADXSD pays

NOBL pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ADXSD

Annual income on $10K today (after 15% tax)

$4,415.58/yr

After 10yr DRIP, annual income (after tax)

$77,324.57/yr

NOBL

Annual income on $10K today (after 15% tax)

$340.00/yr

After 10yr DRIP, annual income (after tax)

$764.31/yr

At 15% tax rate, ADXSD beats the other by $76,560.26/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ADXSD + NOBL for your $10,000?

ADXSD: 50%NOBL: 50%

100% NOBL50/50100% ADXSD

Portfolio after 10yr

$231.8K

Annual income

$45,934.64/yr

Blended yield

19.82%

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ADXSD buys

NOBL buys

No recent congressional trades found for ADXSD or NOBL in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricADXSDNOBL

Forward yield	51.95% ✓	4.00%
Annual dividend / share	$2.00	$2.00
Payout ratio	50%	50%
1-year div growth	0%	5% ✓
5-year div CAGR	0%	5% ✓
Portfolio after 10y	$435.5K ✓	$28.0K
Annual income after 10y	$90,970.08 ✓	$899.19
Total dividends collected	$350.5K ✓	$6.4K
Payment frequency	quarterly	quarterly
Sector	Stock	ETF

Year-by-year: ADXSD vs NOBL ($10,000, DRIP)

Year	ADXSD Portfolio	ADXSD Income/yr	NOBL Portfolio	NOBL Income/yr	Gap
1← crossover	$15,895	$5,194.81	$11,120	$420.00	+$4.8K → ADXSD
2	$24,724	$7,716.86	$12,357	$458.31	+$12.4K → ADXSD
3	$37,673	$11,218.27	$13,721	$499.76	+$24.0K → ADXSD
4	$56,286	$15,975.38	$15,227	$544.58	+$41.1K → ADXSD
5	$82,532	$22,306.57	$16,885	$593.02	+$65.6K → ADXSD
6	$118,878	$30,568.54	$18,713	$645.34	+$100.2K → ADXSD
7	$168,350	$41,149.89	$20,724	$701.81	+$147.6K → ADXSD
8	$234,596	$54,462.14	$22,938	$762.73	+$211.7K → ADXSD
9	$321,946	$70,928.36	$25,372	$828.41	+$296.6K → ADXSD
10	$435,453	$90,970.08	$28,047	$899.19	+$407.4K → ADXSD

ADXSD vs NOBL: Complete Analysis 2026

ADXSD — Stock

Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer. It is also conducting clinical studies of Lm Technology immunotherapies in the following areas of disease focused hotspot/off-the-shelf neoantigen-directed therapies; human papilloma virus-associated cancers; and prostate cancer. The company has collaborations and partnerships with Merck & Co., Inc.; OS Therapies, LLC; Aratana Therapeutics Inc.; Biocon Limited; Global BioPharma Inc.; Knight Therapeutics Inc; and others. Advaxis, Inc. was founded in 2002 and is based in Monmouth Junction, New Jersey.

Full ADXSD Calculator →

NOBL — ETF

NOBL is a dividend-paying stock. Use this calculator to estimate your future dividend income, DRIP compounding returns, and passive income potential from investing in NOBL shares.

Full NOBL Calculator →

📬

Get this ADXSD vs NOBL comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ADXSD vs SCHD ADXSD vs JEPI ADXSD vs O ADXSD vs KO ADXSD vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.